Neuronetrix will be reporting at AAIC 2014 that neuro-electrophysiological measures recorded using the company’s COGNISION System can be used to differentiate patients with mild Alzheimer’s disease from healthy controls. Previous scientific studies have demonstrated the discriminatory power of these measures in highly controlled research environments. Neuronetrix’s study demonstrated that these measures can be reliable recorded and analyzed in real world clinical settings.
The study included over 200 subjects from seven clinical sites across the US. All tests were administered by non-expert clinical staff and the data was automatically analyzed by the COGNISION System. The results include an exhaustive analysis of the complex eletrophysiological features and show their statistical correlation to Alzheimer’s disease.
In addition to their clinical utility, these biomarkers are particularly important in pharmaceutical development of pro-cognitive therapeutics by providing sensitive measures of drug effects.
“This study has confirmed COGNISION System’s ability to bridge the gap between interesting scientific findings and practical clinical applications,” said Marco Cecchi, PhD, Neuronetrix’s Director of Research and Clinical Affairs. “Clinicians and pharmaceutical companies now have access to reliable biomarkers of Alzheimer’s disease in real world clinical settings.”
Study results will be presented at Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark from July 12-17, 2014, during a scientific oral session and at an ISTAART event.